Th heart disease treatment developer has secured $248m in funding since being formed to exploit UT Southwestern and Gladstone Institute research.
Tenaya Therapeutics, a US-based developer of therapies for heart disease based on Gladstone Institutes and University of Texas Southwestern Medical Center research, has filed for an initial public offering.
The company intends to float on the Nasdaq Stock Market and set a $100m placeholder target for the offering.
Tenaya is developing treatments utilising cellular regeneration, gene therapy and precision medicine for a variety of health conditions affecting the heart.
The company will use the IPO proceeds…
